Merck raises annual target ranges
For the first three months of the year, the pharmaceutical company posted non-GAAP EPS up 48% to $2.07, on sales of close to $15.8 billion, up 9% (+12% excluding currency effects).
Merck highlights continued strong revenue growth in oncology and vaccines, with currency-adjusted increases of 24% for its blockbuster Keytruda and 17% for its Gardasil/Gardasil 9 franchise.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction